News coverage about Xenetic Biosciences (NASDAQ:XBIO) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Xenetic Biosciences earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.5209795685534 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Separately, Zacks Investment Research cut shares of Xenetic Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, May 24th.

Shares of Xenetic Biosciences (XBIO) traded down 0.579% during mid-day trading on Friday, reaching $2.406. 6,886 shares of the company’s stock traded hands. Xenetic Biosciences has a 12-month low of $2.41 and a 12-month high of $37.62. The company’s 50 day moving average is $2.80 and its 200 day moving average is $3.45. The company’s market cap is $20.97 million.

Xenetic Biosciences (NASDAQ:XBIO) last issued its earnings results on Monday, August 14th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by $0.13. On average, analysts predict that Xenetic Biosciences will post ($0.89) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/xenetic-biosciences-xbio-earns-daily-news-impact-rating-of-0-08/1538144.html.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.

Receive News & Ratings for Xenetic Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.